Treeline Biosciences, under the leadership of veteran drug hunters Josh Bilenker and Jeff Engelman, emerged from stealth announcing three oncology drug candidates entering clinical trials and a fresh $200 million Series A extension, bringing total capital raised to over $1.1 billion. The portfolio includes their internally discovered protein degrader (TLN-121) targeting BCL6 in lymphoma, a pan-KRAS inhibitor designed to address solid tumors, and an in-licensed EZH2 inhibitor for T-cell lymphomas. The company’s funding strategy aggregates capital upfront to support multiple programs concurrently, aiming for sustained innovation rather than milestone-driven stepwise financing.